New Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs, and Program Leadership Phio ...

Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc.

As specialty medicines account for an increasing share of the drug pipeline, it makes sense for sponsors to support patients financially, emotionally and logistically.

New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional ...

An enterprise AI platform bringing decision-grade intelligence to regulated pharmaceutical operations This partnership ...

President Donald Trump will tap leader of the National Institutes of Health, Jay Bhattacharya, to also serve as acting head ...

The funds are part of Georgia's share of a national settlement with pharmaceutical companies that overprescribed opioids ...

Novel intravenous anti-inflammatory candidate advances to Phase I evaluation to assess safety, tolerability, and ...

Attorneys at Sidley Austin LLP examine the issue of drug price reporting rules under Medicaid and enforcement risks under the False Claims Act.

Henry Ford Health has treated the first Michigan patient outside clinical trials with Roctavian, the newly approved gene ...

Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 2:30 PM ESTCompany ParticipantsJacob Chacko - ...